Carregant...
Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials
OBJECTIVE: Advanced therapy medicinal products (ATMPs) constitute a class of innovative products that encompasses gene therapy, somatic cell therapy, and tissue-engineered products (TEP). There is an increased investment of commercial and non-commercial sponsors in this field and a growing number of...
Guardat en:
| Publicat a: | J Mark Access Health Policy |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Co-Action Publishing
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4973442/ https://ncbi.nlm.nih.gov/pubmed/27570614 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3402/jmahp.v4.32232 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|